Intrathecal administration (pattern 100/3) of expanded autologous adult bone marrow mesenchymal troncal cells in established chronic spinal cord injuries

Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro0 个研究点目标入组 10 人开始时间: 2015年6月1日最近更新: 2018年1月22日

研究概览

暂无简介。

•1.Spinal cord injury (Level A, B, C or D in ASIA scales), clinically stable for at least 6 months prior to study start.
•2.Previous studies of Neurophysiology, MRI and Urology to allow useful baseline, in order that they can be compared with the same scans following treatment, and to obtain objective data of potential efficacy.
•3.Age between 18 and 70 years.
•4.Men and women of childbearing age must compromisse to use contraceptives from the time at which the removal of cells from the bone marrow is performed until 6 months after the MSC last administration by lumbar puncture.
•5.Possibility of follow up and ability to perform ambulatory physical therapy throughout all treatment period.
•6.Written informed consent, according to the law in force.
•7.Hematologic, creatinine, SGOT and SGPT parameters, within the normal range, according to laboratory standards. However, slight modifications that are considered significant in the context of treatment to be performed, according to the criterion of the research team, are accepted.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 9
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 1

•1. Age below 18 years or above 70.
•2. Pregnancy or lactation.
•3. Current neoplastic disease or in the previous 5 years (diagnosed or treated).
•4. Patients with systemic disease that represents an added risk to treatment.
•5. Alterations in the genetic study performed to discard risk cell transformation in the expansion process.
•6. Patients with doubts about possible cooperation in the maintenance physical therapy or in the controls carried out during the study
•7. Neurodegenerative disease added.
•8. History of substance abuse, psychiatric disease or allergy to protein products used in the process of cell expansion.
•9. Positive serology for HIV and syphilis.
•10. Active Hepatitis B or Hepatitis C, according to serology analysis.
•11. If in the opinion of the researcher there is some other reason why the patient is not considered candidate for the study.

发起方

Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro